CorMedix Inc (NASDAQ:CRMD) Stock Has Average Target Price of $15.22

CorMedix Inc (NASDAQ:CRMD – Get Free Report) has been assigned an average recommendation of “Moderate Buy” from the ten analysts that are presently covering the stock, Marketbeat Ratings reports. Two research analysts have rated the stock with a hold recommendation and eight have issued a buy recommendation on the company. The average 1-year price target among brokers that have issued a report on the stock in the last year is $15.22.

Several research analysts have recently commented on the company. Needham & Company LLC boosted their price objective on CorMedix from $12.00 to $14.00 and gave the stock a “buy” rating in a report on Tuesday, November 10th. Royal Bank Of Canada boosted their target price on CorMedix from $14.00 to $15.00 and gave the company an “outperform” rating in a research note on Tuesday, November 10th. Wall Street Zen cut shares of CorMedix from a “hold” rating to a “sell” rating in a research report on Saturday, November 14th. Citigroup reissued a “market outperform” rating on shares of CorMedix in a research note on Tuesday, November 10th. Finally, Oppenheimer reissued an “outperform” rating and issued a $13.00 price target (down from $15.00) on shares of CorMedix in a research note on Friday, November 13th.

Check Out Our Latest Report on CorMedix

CorMedix Stock Performance

Shares of CRMD opened at $5.27 on Friday. CorMedix has a 52-week low of $4.47 and a 52-week high of $13.02. The stock has a market capitalization of $419.18 million, a price-to-earnings ratio of 7.64, a price-to-earnings-growth ratio of 1.21 and a beta of 1.48. The company has a debt-to-equity ratio of 0.31, a quick ratio of 2.36 and a current ratio of 2.43. The stock’s 50-day simple moving average is $6.86 and its 200 day simple moving average is $7.49.

CorMedix (NASDAQ:CRMD – Get Free Report) last issued its quarterly earnings data on Thursday, November 12th. The company reported ($0.19) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.07). CorMedix had a net margin of 15.49% and a return on equity of 26.70%. The firm had revenue of $54.52 million for the quarter, compared to analysts’ expectations of $51.76 million. Research analysts forecast that CorMedix will post 0.44 EPS for the current fiscal year.

Insider Buying and Selling

In other CorMedix news, Director Steven Lefkowitz bought 11,500 shares of the firm’s stock in a transaction on Wednesday, November 18th. The stock was acquired at an average price of $4.53 per share, with a total value of $52,095.00. Following the completion of the purchase, the director owned 137,451 shares of the company’s stock, valued at approximately $622,653.03. This trade represents a 9.13% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Myron Kaplan purchased 25,000 shares of the business’s stock in a transaction that occurred on Monday, November 16th. The stock was bought at an average price of $4.88 per share, for a total transaction of $122,000.00. Following the purchase, the director directly owned 256,487 shares in the company, valued at $1,251,656.56. The trade was a 10.80% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders have acquired 121,500 shares of company stock valued at $588,195 over the last quarter. Corporate insiders own 3.50% of the company’s stock.

Hedge Funds Weigh In On CorMedix

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. BlackRock Inc. bought a new stake in shares of CorMedix in the second quarter worth $49,644,000. American Century Companies Inc. grew its stake in shares of CorMedix by 688.5% in the 3rd quarter. American Century Companies Inc. now owns 2,722,920 shares of the company’s stock worth $20,966,000 after buying an additional 2,377,579 shares in the last quarter. Goldman Sachs Group Inc. increased its position in shares of CorMedix by 167.9% during the 3rd quarter. Goldman Sachs Group Inc. now owns 1,249,382 shares of the company’s stock valued at $9,620,000 after purchasing an additional 782,989 shares during the last quarter. Marshall Wace LLP raised its position in CorMedix by 53.4% in the 3rd quarter. Marshall Wace LLP now owns 1,195,422 shares of the company’s stock worth $9,205,000 after purchasing an additional 415,887 shares during the period. Finally, Pacer Advisors Inc. raised its holdings in shares of CorMedix by 128.7% in the first quarter. Pacer Advisors Inc. now owns 580,620 shares of the company’s stock worth $3,942,000 after buying an additional 326,724 shares during the period. Institutional investors own 34.18% of the company’s stock.

CorMedix Company Profile

(Get Free Report)

CorMedix Inc. is a biopharmaceutical company focused on products for infectious and inflammatory diseases. Its lead product, DefenCath, is an antimicrobial catheter-lock solution containing taurolidine and heparin. The U.S. Food and Drug Administration approved it to reduce catheter-related bloodstream infections in adults with kidney failure who receive chronic hemodialysis through a central venous catheter. CorMedix expanded its business in 2024 by acquiring Melinta Therapeutics, adding marketed antibiotics to its portfolio.

Featured Stories

Analyst Recommendations for CorMedix (NASDAQ:CRMD)

Receive News & Ratings for CorMedix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CorMedix and related companies with MarketBeat.com's FREE daily email newsletter.